Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements

Yongkun Sun, Wen Zhang, Xinyu Bi, Zhengqiang Yang, Yu Tang, Liming Jiang, Feng Bi, Minshan Chen, Shuqun Cheng, Yihebali Chi, Yue Han, Jing Huang, Zhen Huang, Yuan Ji, Liqun Jia, Zhichao Jiang, Jing Jin, Zhengyu Jin, Xiao Li, Zhiyu LiJun Liang, Lianxin Liu, Yunpeng Liu, Yinying Lu, Shichun Lu, Qinghua Meng, Zuoxing Niu, Hongming Pan, Shukui Qin, Wang Qu, Guoliang Shao, Feng Shen, Tianqiang Song, Yan Song, Kaishan Tao, Aiping Tian, Jianhua Wang, Wenling Wang, Zhe Wang, Liqun Wu, Feng Xia, Baocai Xing, Jianming Xu, Huadan Xue, Dong Yan, Lin Yang, Jianming Ying, Jingping Yun, Zhaochong Zeng, Xuewen Zhang, Yanqiao Zhang, Yefan Zhang, Jianjun Zhao, Jianguo Zhou, Xu Zhu, Yinghua Zou, Jiahong Dong, Jia Fan, Wan Yee Lau, Yan Sun, Jinming Yu, Hong Zhao, Aiping Zhou, Jianqiang Cai

Research output: Contribution to journalReview articlepeer-review


Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China, it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease. Summary: For more than a decade, sorafenib, a small-molecular-weight tyrosine kinase inhibitor (SMW-TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors for advanced HCC, the management of patients has been greatly improved. However, though angiogenic-based targeted therapy remains the backbone for the systemic treatment of HCC, to date, no Chinese guidelines for novel molecular targeted therapies to treat advanced HCC have been established. Our interdisciplinary panel on the treatment of advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, pathologists, orthopedic surgeons, traditional Chinese medicine physicians, and interventional radiologists has reviewed the literature in order to develop updated treatment regimens. Key Messages: Panel consensus statements for the appropriate use of new molecular -targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation, and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals.

Original languageEnglish
Pages (from-to)192-208
Number of pages17
JournalLiver Cancer
Issue number3
StatePublished - Jun 4 2022
Externally publishedYes


  • Chinese interdisciplinary experts
  • Consensus
  • Hepatocellular carcinoma
  • Molecular targeted therapy


Dive into the research topics of 'Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements'. Together they form a unique fingerprint.

Cite this